We are pleased to announce that as of October 1, 2016, Elizabeth (Lisa) Henske, MD, is the newest director of the Brigham Research Institute (BRI). Lisa has previously been co-director of the BRI and will serve as BRI Director for the next two years.
Lisa is best known for her groundbreaking discovery that mutations in the TSC2 gene cause the sporadic form of lymphangioleiomyomatosis (LAM). This provided the foundation for pivotal clinical trials demonstrating the efficacy mammalian/mechanistic target of rapamycin (mTOR) inhibitors for the treatment of LAM. Her laboratory has also discovered that autophagy plays a critical role in the pathogenesis and therapy of LAM, leading to an ongoing clinical trial called the “SAIL” trial: Sirolimus and Autophagy Inhibition in LAM.